ALDX
NASDAQAldeyra Therapeutics Inc.
Price$1.83-0.04 (-2.14%)
01:30 PM02:45 PM
News · 26 weeks22-60%
2025-12-142026-06-07
Mix1590d
- SEC Filings6(40%)
- Other4(27%)
- Insider4(27%)
- Analyst1(7%)
Latest news
25 items- INSIDERPresident and CEO Brady Todd C bought $418,450 worth of shares (250,000 units at $1.67), increasing direct ownership by 17% to 1,721,298 units (SEC Form 4)4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
- PRAldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York, New York. Dr. Brady's conversation with Amin Makarem, Vice President, Biotechnology Equity Research at Jefferies, is scheduled to begin at 8:45 a.m. ET Thursday, June 4, 2026. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webca
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.SCHEDULE 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
- SECSEC Form 10-Q filed by Aldeyra Therapeutics Inc.10-Q - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- SECSEC Form DEFA14A filed by Aldeyra Therapeutics Inc.DEFA14A - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- SECSEC Form DEF 14A filed by Aldeyra Therapeutics Inc.DEF 14A - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- SECAldeyra Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- SECSEC Form 8-K filed by Aldeyra Therapeutics Inc.8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- INSIDERSEC Form 4 filed by Brady Todd C4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.SCHEDULE 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
- INSIDERSEC Form 4 filed by Douglas Richard4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
- INSIDERSEC Form 4 filed by Alfieri Michael4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
- ANALYSTAldeyra Therapeutics downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Aldeyra Therapeutics from Buy to Neutral and set a new price target of $2.00
- SECAldeyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- PRAldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye DiseaseAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The CRL stated that there is "a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labe
- SECSEC Form S-8 filed by Aldeyra Therapeutics Inc.S-8 - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- SECSEC Form 10-K filed by Aldeyra Therapeutics Inc.10-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- PRAldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Dr. Brady's conversation with Andreas Argyrides, Managing Director, Senior Biotech Analyst at Oppenheimer & Co. Inc., is scheduled to begin at 10:40 a.m. ET Wednesday, February 25, 2026. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.SCHEDULE 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
- SECSEC Form 8-K filed by Aldeyra Therapeutics Inc.8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- SECAldeyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- PRAldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye DiseaseAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. Following submission on June 16, 2025, the NDA was accepted for review as a "complete class 2 response" by the FDA on July 16, 2025, with a target PDUFA action date of December 16, 2025. On December 12, 2025, the FDA met with Aldeyra to r
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.SCHEDULE 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
- SECAldeyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
- PRAldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development WebcastAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a research and development webcast the expansion of the RASP platform to include programs in central nervous system diseases associated with inflammation, and provided updated manufacturing information on reproxalap. Based on new preclinical results in models of Parkinson's disease and amyotrophic lateral sclerosis, which included improved grip strength, balance, and biomarkers of central nervous system function, potential clinical indications for the orally administered, next-generation RASP
ALDX FAQ
7 questionsWhat does Aldeyra Therapeutics Inc. do?
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small...Where does ALDX stock trade?
Aldeyra Therapeutics Inc. (ALDX) is listed on NASDAQ.What sector and industry is ALDX in?
Aldeyra Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aldeyra Therapeutics Inc. go public?
Aldeyra Therapeutics Inc. (ALDX) completed its IPO in 2014.What are analysts saying about ALDX?
Aldeyra Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $200.00 price target on 2026-03-18.What companies are similar to ALDX?
Notable peers in the same industry include RLMD (Relmada Therapeutics Inc.), ACRS (Aclaris Therapeutics Inc.), ATXI (Avenue Therapeutics Inc.), APVO (Aptevo Therapeutics Inc.). Compare ALDX side-by-side with any of them on Quantisnow.How can I track ALDX on Quantisnow?
Quantisnow aggregates Aldeyra Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALDX to receive live email and push alerts on every new disclosure.